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Abstract
Background: Recently, two large genome wide association studies in Alzheimer disease (AD) have identified variants in
three different genes (CLU, PICALM and CR1) as being associated with the risk of developing AD. The strongest association
was reported for an intronic single nucleotide polymorphism (SNP) in CLU.
Methodology/Principal Findings: To further characterize this association we have sequenced the coding region of this
gene in a total of 495 AD cases and 330 healthy controls. A total of twenty-four variants were found in both cases and
controls. For the changes found in more than one individual, the genotypic frequencies were compared between cases and
controls. Coding variants were found in both groups (including a nonsense mutation in a healthy subject), indicating that
the pathogenicity of variants found in this gene must be carefully evaluated. We found no common coding variant
associated with disease. In order to determine if common variants at the CLU locus effect expression of nearby (cis) mRNA
transcripts, an expression quantitative loci (eQTL) analysis was performed. No significant eQTL associations were observed
for the SNPs previously associated with AD.
Conclusions/Significance: We conclude that common coding variability at this locus does not explain the association, and
that there is no large effect of common genetic variability on expression in brain tissue. We surmise that the most likely
mechanism underpinning the association is either small effects of genetic variability on resting gene expression, or effects
on damage induced expression of the protein.
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Introduction
Alzheimer’s disease (AD) is recognized as a complex and
multifactorial disease, in which genetics represents a significant
role. A small subset of early onset AD cases (EOAD) are associated
with mutations in three genes (APP, PSEN1 and PSEN2). Most
cases present with late onset of the disease (LOAD) without
familial aggregation and are said to be sporadic. Several studies
have tried to uncover the genetic basis of these late onset cases, but
until recently, the only well established genetic risk factor
associated with LOAD was ApoE [1]. In the past five years, the
development of platforms able to genotype millions of SNPs and of
powerful analytical frameworks able to distinguish true associa-
tions, together with the completion of the International Human
HapMap project, have revealed risk factors associated with a wide
variety of complex disorders [2].
Recently, the two largest AD GWAS reported three genes (CLU,
PICALM and CR1) reaching genome wide significance when
studying over 16000 individuals. In these studies, the most
significant hit (rs11136000) is located in an intron of CLU, on
chromosome 8 [3,4].
Clusterin or apolipoprotein J is a lipoprotein expressed in most
mammalian tissues with higher levels in brain, ovary, testis and
liver [5]. It has been suggested to be involved in a variety of
physiological processes, such as, ongoing synapse turnover [6],
apoptosis [7,8], cytoprotection at fluid-tissue boundaries, mem-
brane recycling during development and in response to injury and
regulation of complement-mediated membrane attack complex
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[9,10]. Accordingly, CLU interacts with several different mole-
cules, including lipids, amyloid proteins, components of the
complement membrane attack complex and immunoglobulins
[9]. From a biological point of view, it seems to have a potential
central role in the pathogenesis of Alzheimer’s disease. When
control brains are compared with AD brains, CLU mRNA is
found to be significantly elevated in AD affected brain areas
[10,11]. Clusterin is one of the proteins found to be part of
amyloid plaques, the main neuropathological hallmarks of AD
[12,13,14,15]. Clusterin specifically binds soluble Ab in cerebro-
spinal fluid [16,17] to form complexes able to cross the blood-
brain barrier [18]. It has also been noted that reduced levels of
ApoE and increased levels of CLU are correlated with the number
of E4 alleles, suggesting a compensatory induction of CLU in the
brain of AD individuals with the E4 allele of ApoE presenting low
brain levels of ApoE [19].
Because of the genetic and biological evidence suggesting a role
for CLU in AD, we sought to characterize the common genetic
coding variability in this gene. To accomplish this, we compared
the genetic variation found in exon 5 of CLU (where rs7982 is
located), between a total of 849 AD cases and 1067 neurologically
healthy controls. Additionally, since it is now clear that common
risk alleles and rare mutations in the same gene may contribute to
common sporadic and familial forms of the same disease,
respectively; we searched for rare mutations that could be related
to familial AD cases in our sample. For this reason, we sequenced
the entire coding region of CLU in a total of 495 AD cases and 330
controls.
The absence of common coding variants able to explain the
association with disease observed by Harold et al and Lambert et
al, suggested a potential implication of differential gene expression
or splicing changes of the gene [3,4]. In order to determine if
common variants within these regions effect expression of nearby
(cis) mRNA transcripts we conducted an expression quantitative
loci (eQTL) analysis for CLU genomic region, for gene expression
in cortical tissues from a group of 174 neurologically normal
controls (GEO Series GSE8919, Myers et al 2007).
Results
Sequencing Analysis
A total of twenty-four variants were found in both cohorts.
From these, eleven were observed in only one subject (Table 1).
These eleven variants include synonymous changes (c.126C.G,
p.T42T; c.132G.A, p.A44A; c.279C.T, p.Y93Y; c.348C.T,
p.N116N; c.438G.A, p.K146K; and c.879C.T, p.H293H),
suggesting no functional change for the protein; non-synonymous
variants observed in controls and AD patients (c.284A.G,
p.N95S; c.764C.T, p.T255I and c.1013G.A, p.R338Q); a
nonsense mutation identified in a control individual (c.40G.T,
p.E14X); and an in-frame deletion (c.812_814delTCT, p.F272del)
present in a control individual.
Ten variants were found in more than one individual in the
Portuguese series and seven in the UK series. The genotypic
frequencies for these variants were compared between cases and
controls (Tables 2 and 3). From these, four variants were found in
both cohorts (p.T255I, p.H315H, rs3216167 and p.D380D).
No statistical significant differences were observed for any of the
genetic variants found in more than one individual, between cases
and controls.
In order to predict the impact in protein function of the non-
synonymous variants found in CLU, we performed an in silico
analysis using PolyPhen (Tables 1–3). From the eight coding,
missense and non-synonymous changes found in CLU, three were
considered to possibly affect the protein function (p.R234H,
p.P322L and p.N369H) while the other five were predicted to be
benign. Nonetheless, these three variants are most likely non-
pathogenic, since they have been found both in cases and healthy
controls (Tables 2 and 3).
Exons 5 (where the common H315H polymorphism is located)
and 6 of CLU (where a non-synonymous change, p.R338Q, was
found in a patient and was absent from controls) were screened in
an additional set of 200 control individuals from Portugal.
p.R338Q was not found in these additional 200 control samples
(Figure 1).
Table 1. Changes (synonymous and non-synonymous) found in CLU and observed in only one subject (AD case or control) in both
series.
Variants seen in only one subject Sample
Location in
the gene DNA change Protein change
Present in
dbSNP
PolyPhen prediction
of pathogenicity
(PSIC score) Diagnosis Sex Age AAO Fam hist Origin
59UTR c.290G.A N.A. no - Ctrl M - N.A. N.A. UK
1 c.40G.T p.E14X No - Ctrl M 69 N.A. N.A. PT
1 c.126C.G p.T42T No - Ctrl F 70 N.A. N.A. PT
2 c.132G.A p.A44A No - AD M 76 73 Pos PT
3 c.279C.T p.Y93Y rs9331898 - MCI F 78 - - PT
3 c.284A.G p.N95S No Benign (1.298) Ctrl M 59 N.A. N.A. PT
3 c.348C.T p.N116N No - AD F 59 59 Neg PT
4 c.438G.A p.K146K No - Ctrl F 69 N.A. N.A. PT
5 c.812_814delTCT p.F272del No - Ctrl F 28 N.A. N.A. UK
5 c.879C.T p.H293H No - AD F 73 72 - PT
6 c.1013G.A p.R338Q No Benign (1.471) AD F 51 - - PT
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequences (CLU: NM_001831.2).
The initiation codon is codon 1. Genomic numbering refers to reference sequence NC_000008.9. Protein numbering refers to sequence NP_001822.2. AAO: age at onset;
Fam hist: Family history; N.A.: not applicable; -: information not available. Prediction of pathogenicity was performed in silico using the PolyPhen software [27,28,29].
doi:10.1371/journal.pone.0009510.t001
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eQTL Analysis
eQTL analysis did not reveal any statistically significant results
within the immediate region of AD associated loci for CLU
(Figure 2). We were, however, able to confirm that CLU levels are
higher in AD cases than in controls (GSE15222) [11,20], though
this is difficult to interpret because of the changing cellular
composition of diseased tissue.
Discussion
We sequenced the coding region CLU in 495 AD patients and
330 controls and exon 5 in a total of 849 AD cases and 1067
controls. This approach allowed us to find several new variants
and, for some changes, compare the genotypic and allelic
frequencies between cases and controls. Although variants in
other exons are in LD with the previously associated SNPs, exon 5
was of particular significance, since this is the only exon where a
potential functionally interesting coding SNP with a minor allele
frequency (MAF) above 0.05 was identified (rs7982, p.H315H).
Additionally, this was the only exon where coding variants were
found in more than one individual in the UK series (p.R234H,
p.T255I and p.P322L).
Our results are consistent with an association in the same
direction for rs7982 (p.H315H) reported by Harold et al. The
minor allele frequencies for this variant observed in the Portuguese
and UK control series did not differ from those described by
Harold et al (MAF in Portuguese controls: 0.37; MAF in UK
controls: 0.40; MAF in Harold et al: 0.40). The failure to achieve
statistical significance is most likely due to the small number of
samples studied here, considering the marginal odds ratios
associated with this variant (meta-analysis of the combined sample
OR=0.86, based on partially imputed genotypes in Harold et al)
Table 2. Variants found in CLU observed in more than one individual in the Portuguese series.
Location in
the gene DNA change
Protein
change
Present in
dbSNP
Frequency
affected
Frequency
unaffected P OR
PolyPhen
prediction of
pathogenicity
(PSIC score)
Exon 1 c.48C.A p.S16R No 0.01425 0.01878 0.5459 0.7517 Benign (1.125)
Exon 2 c.240C.T p.D80D rs9331892 0.005181 0.007653 0.6074 0.6736 -
Exon 5 c.945T.C p.H315H rs7982 0.3575 0.3716 0.6296 0.9429 -
IVS6 g.27517690 -/A NA rs3216167 0.2642 0.2269 0.1449 1.233 -
Exon 7 c.1105A.C p.N369H rs9331936 0.008174 0.002358 0.2469 3.507 Possibly damaging
(1.557)
Exon 7 c.1110C.G p.P370P rs9331937 0.001362 0.002358 0.6975 0.5765 -
Exon 7 c.1138G.A p.D380N rs9331938 0.002725 0.002358 0.9059 1.156 Benign (0.322)
Exon 7 c.1140C.T p.D380D rs9331939 0.001362 0.004717 0.3092 0.2869 -
39UTR g.27511359 T/C NA rs3087554 0.1425 0.1302 0.5646 1.112 -
39UTR g.27511354 C/T NA no 0.007634 0.005208 0.5001 1.723 -
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequences (CLU: NM_001831.2).
The initiation codon is codon 1. Genomic numbering refers to reference sequence NC_000008.9. Protein numbering refers to sequence NP_001822.2. Prediction of
pathogenicity was performed in silico using the PolyPhen software [27,28,29].
doi:10.1371/journal.pone.0009510.t002
Table 3. Variants found in CLU observed in more than one individual in the UK series.
Location in the
gene DNA change
Protein
change
Present in
dbSNP
Frequency
affected
Frequency
unaffected P OR
PolyPhen
prediction of
pathogenicity
(PSIC score)
59UTR c.-229G.C NA no 0.34 0.27 0.11 1.50 -
Exon 5 c.701G.A p.R234H no 0.001 0.002 0.51 0.47 Possibly damaging
(1.641)
Exon 5 c.764C.T p.T255I rs41276297 0.003 0.006 0.35 0.53 Benign (0.310)
Exon 5 c.945T.C p.H315H rs7982 0.38 0.40 0.41 0.93 -
Exon 5 c.965T.C p.P322L no 0.002 0.002 0.73 1.42 Possibly damaging
(1.963)
IVS6 g.27517690 -/A NA rs3216167 0.34 0.25 0.04 1.68 -
Exon 7 c.1140C.T p.D380D rs9331939 0.01 0.02 0.68 0.68 -
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequences (CLU: NM_001831.2).
The initiation codon is codon 1. Genomic numbering refers to reference sequence NC_000008.9. Protein numbering refers to sequence NP_001822.2. p values
presented here are uncorrected for multiple testing(none is statistically significant after Bonferronni correction). Prediction of pathogenicity was performed in silico
using the PolyPhen software [27,28,29].
doi:10.1371/journal.pone.0009510.t003
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we only had ,20% power to detect an effect of this magnitude in
either cohort [3].
From the 14 variants found in more than one individual, none
was found to be significantly associated with the development of
AD. In the UK cohort, rs3216167 was found to have a nominal
un-corrected p value of 0.04 (OR=1.68, Table 3). A meta-analysis
between the two cohorts revealed a similar value (p= 0.03 for
random-effects meta-analysis, data not shown). This is a common
SNP located in intron 6 that has previously been reported by
Miwa Y. and colleagues to be associated with increased serum
levels of total and LDL cholesterol, intima-media complex
thickness of the common carotid artery and atherogenic plaque
prevalence in Japanese hypertensive females [21]. Although a
previous study of the distribution of polymorphisms in CLU in AD
also found no individual coding or non-coding variants consis-
tently associated with the disease, variants such as H369N and
D380N have been reported to impact the levels of serum HDL
cholesterol, HDL2, HDL3 and ApoA1 in African individuals
[22,23].
The sequencing of the gene allowed us to search for mutations
that could be the cause of the disease in early onset AD cases.
This is clearly of importance, since in many cases, common
genetic variation associated with late onset common disease has
been found in the same genes where mutations are known to
cause early onset familial forms of the disease [24,25]. A total of
twenty-four variants was found, from which four were non-
synonymous coding changes present in only one subject. Three of
these changes (p.E14X, p.N95S and p.F272del) were found in
controls and one (p.R338Q) was found in an early onset female
AD patient. The screening of this variant in 200 additional
Portuguese controls revealed a total of 1067 healthy individuals
not harboring the p.R338Q change. Nonetheless, the lack of
segregation data, the nonexistence of functional data for this
variant and the in silico prediction by PolyPhen of non-
pathogenicity, support a benign outcome for this genetic change
in AD pathogenicity.
From the eight coding, non-synonymous changes found, three
were predicted by PolyPhen to be possibly damaging (p.R234H,
p.P322L and p.N369H). All of these were present in cases and
controls, indicating that most probably these are also non-
pathogenic variants. The finding of variants in controls, particu-
larly the finding of a nonsense mutation in a 69 years old healthy
individual, clearly adds to the requirement of an extended
evaluation of the pathogenicity of each variant.
The sequencing approach used in this study, allowed us to
compare not only one of the variants previously associated with
AD (p.H315H) [3], but also, all the coding variants, the changes
located in the exon-intron boundaries and in the 59 and 39
untranslated regions of CLU.
These largely negative results strongly suggest that: (1) the
association signal reported by the two whole genome
associations is unlikely to be caused by a common coding
Figure 1. Summary of the samples used in this study and the type of genetic analysis of CLU performed in each subset. ECCAC -
European Collection of Cell Cultures; CEPH - Centre d’Etude du Polymorphisme Humain.
doi:10.1371/journal.pone.0009510.g001
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variant, such as is seen in APOE; (2) rare coding variants are
not likely to be responsible for familial disease; and (3) that
large eQTL effects in control tissue do not underlie the
association. The possibilities that remain to explain the genetic
association are that either there are small eQTL effecting
expression (simulation studies suggest a study of this size could
identify allelic effects of ,20%) or that genetic variability in
induced expression is the key issue.
Materials and Methods
Ethics Statement
All subjects included in this study, or their surrogates, gave
written informed consent. This study and the use of these samples
were approved for genetic research by: University College London
Hospitals; National Hospital for Neurology and Neurosurgery;
Coimbra University Hospital and National Institute of Health
Figure 2. Manhattan plots for eQTL p-values +/2 250Kb of the previously AD associated regions near CLU. For this plot the x-axis
represents the physical region of the chromosome and the y-axis is the –log10 of the asymptotic p-values from the eQTL analyses. The horizontal
black dashed line represent the statistically significant threshold based on a Bonferonni correction for the number of SNPs and mRNA transcripts
tested, while the black dotted represent the suggestive threshold based on the average number of SNPs tested per transcript. The relative positions
of previously disease associated SNPs are denoted by vertical black lines. The individual p-values points for the SNP/Transcript tests are indicated by
color and number so that the most significant values are the dark red ‘5’s for SCARA3 and the blue ‘6’s for CCDC25. In the plots the transcripts
depicted are not all mRNA transcripts within the region but are instead the transcripts within the region with a probe present on the expression array
and was well detected within the sample series.
doi:10.1371/journal.pone.0009510.g002
CLU Genetic Variability in AD
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Ethics Committees. The study was conducted according to the
principles of the Helsinki Declaration.
Sequencing Analysis (Figure 1)
Portuguese series. After obtaining written informed consent
from all participants or surrogates, blood samples were collected
and DNA extracted from a total of 403 AD patients (62% of cases
were women). All these were white with apparent Portuguese
ancestry. The mean age of AD patients was 70 years old and mean
age at onset was 67 years, ranging from 42 to 86 years. The genes
associated with EOAD (PSEN1, PSEN2 and APP) have been
previously sequenced in all early onset cases (88 cases, with an age
at onset before 65 years old) and no mutations were found [26].
Written informed consent was obtained from 235 neurologically
normal and aged control subjects from Portugal (mean age at
collection 68 years, 58% women). All controls were subjected to a
neurological examination and found free of any symptoms
suggestive of cognitive decline. This study and the use of these
samples were approved for genetic research by the Coimbra
University Hospital and National Institutes of Health Ethics
Committees.
UK series. After obtaining written informed consent from all
participants or surrogates, blood samples were collected from 489
AD patients (59% of cases were women). This study and the use of
these samples were approved for genetic research by the University
College LondonHospitals and National Hospital for Neurology and
Neurosurgery Research Ethics Committees. DNA was extracted
using established protocols. A total of 476 cases were of UK origin, 5
were of other European origin, 2 were of non-European origin and
6 were of unknown origin. Patients were referred from the
Dementia Research Centre, National Hospital for Neurology,
Queen Square, UK, or other specialist cognitive teams in the UK,
with either a clinical diagnosis of AD, or alternatively with cognitive
impairment and referred for APP, PSEN1 or PSEN2 gene analysis.
The mean age of onset was 54 years with a range of 21–78 years.
One or more of the genes causally associated with EOAD (PSEN1,
PSEN2 and APP) and with prion disease (PRNP) were screened and
found to be negative for mutations in 207 cases. PRNP alone was
found to be negative for mutation in a further 88 cases, and the
remaining 194 cases were not screened.
A total of 440 white healthy control DNAs were obtained from
ECCAC (European Collection of Cell Cultures) and 192 unrelated
individuals from the CEPH (Centre d’Etude du Polymorphisme
Humain). Appropriate consent was available for all control
individuals.
DNA sequencing and data analysis. Sequencing analysis of
CLU (GeneID: 1191; isoform 1: NM_001831.2, which is the
longest transcript of the gene, encoding 9 exons) was carried out
using genomic DNA of a total of 638 Portuguese samples (403 AD
cases and 235 neurologically normal controls) and 187 UK
samples [92 AD patients and 95 UK healthy controls (ECCAC)].
All the coding exons plus the flanking intron-exon boundaries of
CLU were PCR amplified using primers (available on request)
designed using ExonPrimer software (http://ihg2.helmholtz-
muenchen.de/ihg/ExonPrimer.html) and Roche FastStart PCR
MasterMix polymerase (Roche Diagnostics Corp., IN). Each
purified PCR product was sequenced using Applied Biosystems
BigDye terminator v3.1 sequencing chemistry and run on an
ABI3730xl (Applied Biosystems, CA) genetic analyzer as per
manufacturer’s instructions. The sequences were analyzed with
Sequencher software, version 4.2 (Genecodes, VA).
Further 354 AD patients, 345 UK healthy controls (ECCAC)
and 192 unrelated CEPH individuals were sequenced for exon 5 of
CLU only. Genotypes for rs7982 were confirmed by realtime PCR
using MGB allelic discrimination probes in all UK cases described
above and an additional 43 definite AD cases.
In order to predict the impact in protein function of the non-
synonymous variants found in CLU we performed an in silico
analysis using PolyPhen [27,28,29].
SNPs were tested for association with Alzheimer’s disease using
logistic regression, assuming an additive model. These tests were
performed using PLINK v1.07 [30]. In order to avoid any
potential stratification effect, only the cases with known European
ancestry were included in this analysis (13 samples from the UK
series were excluded from the association analysis).
eQTL Analysis
Since no gene expression data were available from the
populations in which the sequencing analysis was performed, we
used genotype and gene expression data from 174 neurologically
normal controls from the United States, obtained from our
previously published eQTL analysis [31]. Gene expression data
are available at NCBI’s Gene Expression Omnibus (GEO Series
Accession, GSE8919) and genotype data are available from
TGEN (http://www.tgen.org/research/neuro_gab2.cfm). Based
on genotype data samples were checked for quality of genotyping
based upon genotype call rate per sample, population outliers
using Structure [32,33] and Plink and for cryptic relatedness and
gender discrepancies with Plink [30].
Genotype data were from the Affymetrix GeneChip Human
Mapping 500 K Array Set, which assays 502,627 SNPs (Affymetrix,
Santa Clara, CA). Genotypes were imputed based on HapMap data
using the IMPUTE program resulting in genotype call for 1741175
SNPs after QC of imputed data. Based upon SNP selection criteria
of Hardy-Weinberg Equilibrium p-value .0.001 and the presence
of at least 3 minor homozygotes, 322 SNPs were selected for cis
regional eQTL analysis near CLU, being the cis region defined as
centered on the AD associated locus +/2 250 Kb. Gene expression
data were from the Illumina HumanRef-8 v1 Expression BeadChip
that assays 24,357 RefSeq mRNA transcripts (Illumina Inc., San
Diego, CA). Expression data were rank invariant normalized
[34,35,36] using Illumina’s BeadStudio Gene Expression module.
Expression mRNA transcripts were selected for analysis based upon
whether they reliable detected within 95% of samples, are within the
cis genomic regions of interest and where the probes designed to
assay the mRNA transcript did not contain a common polymor-
phism that have been typed within the HapMap CEU population.
This resulted in 6 mRNA transcripts being selected for analysis,
including one CLU transcript. Prior to eQTL analysis each of the
normalized transcript expression profiles was log2 transformed and
adjusted for available covariates (age at death, gender, cortical
region, post mortem interval, tissue bank source and RNA
preparation/hybridization batch) by linear regression, the residuals
of these regressions were then used as the quantitative trait for
eQTL analysis.
The eQTL analysis was performed using Plink’s [30] assoc
function for quantitative traits, which correlates allele dosage with
changes in the trait. To correct for the number of tests performed,
a Bonferroni correction was applied to the asymptotic p-values
based 322 SNPs tested against 6 transcripts in the CLU region.
This Bonferroni correction for 1932 tests resulted in a significance
threshold of 2.587992e-05 for asymptotic p-values.
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